Transplanted kidneys from living donors survive longer with Neoral compared with ...( Basel June 3rd 2003 The long-term ch...),Health

Basel, June 3rd 2003 The long-term chances of survival of a transplanted kidney from a living donor are significantly greater with immunosuppressive therapy based on Neoral (cyclosporin microemulsion) than with therapy based on tacrolimus, according to a major new study presented today at this year's American Transplant Congress in Washington, DC, USA.1 Immunosuppressive therapy is used to help prevent the body from rejecting a transplanted organ.

Over 40% of all new kidney transplant patients in the USA receive an organ from a living donor.2 The retrospective study assessed data from over 7,000 living donor kidney transplant recipients registered within the US organ transplant registry United Network for Organ Sharing (UNOS) and aimed to compare organ survival over three years in patients receiving one of the two most commonly used immunosuppressive regimens: Neoral or tacrolimus, both in combination with mycophenolate mofetil and steroids.

The study concluded that three-year graft (organ) survival rates for the transplanted kidney were significantly higher in patients who received Neoral compared to patients who received tacrolimus. Specifically, the results showed that:

• patients who received tacrolimus had a 28% higher risk of losing their transplanted organ or of dying (all cause graft failure) than patients who received Neoral (hazard ratio of 1.28). When patients who died with a functioning organ were excluded from the analysis of organ failures, patients treated with tacrolimus had a 25% higher risk of losing their organ (hazard ratio of 1.25).

• transplanted kidneys in patients who were taking Neoral were expected to survive for four years longer on average than in patients taking tacrolimus, according to the results of another prognostic tool, the 'estimated graft half-life' (20.8 years graft half-life survival time for the Neoral group vs 16.1 years for the tacrolimus group, all cause graft failure).
  '"/>

Contact: Kajsa McLaren
kajsa.mclaren@shirehealthinternational.com
44-20-7471-1515
Shire Health International
3-Jun-2003


Page: 1 2 3
Related medicine news :

1. Transplanted bone marrow cells reduce liver fibrosis in mice
2. Transplanted human neural stem cells improve memory in rats
3. New Strategy May Succeed At Extending The Life Of Transplanted Kidneys
4. Therapy Developed At Cedars-Sinai Medical Center Shows Promise In Preventing Rejection Of Transplanted Organs
5. Bone Marrow With Heart And Lung Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
6. Bone Marrow With Organ Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
7. Investigational transplant drug effectively preserves kidneys while avoiding toxic side effects
8. Matching method helps doctors successfully transplant higher-risk kidneys
9. Clinical trial shows drug may offer a new option to prevent rejection of transplanted kidneys
10. Mechanism found that may protect kidneys in early stages of diabetes
11. Would it be worth it to pay for donated kidneys?